In other words, the price has increased by $0.0000 from its previous closing price. On the day, 2555468 shares were traded.
Ratios:
Our goal is to gain a better understanding of BLUE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.42 and its Current Ratio is at 1.55. In the meantime, Its Debt-to-Equity ratio is 1.36 whereas as Long-Term Debt/Eq ratio is at 1.04.
On December 08, 2023, Morgan Stanley Upgraded its rating to Equal-Weight which previously was Underweight and also upped its target price recommendation from $3 to $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 04 ’24 when Obenshain Andrew sold 6,095 shares for $1.53 per share. The transaction valued at 9,311 led to the insider holds 279,998 shares of the business.
Klima Thomas J sold 4,573 shares of BLUE for $6,986 on Mar 04 ’24. The insider now owns 124,840 shares after completing the transaction at $1.53 per share. On Mar 01 ’24, another insider, Colvin Richard A, who serves as the Chief Medical Officer of the company, sold 6,770 shares for $1.53 each. As a result, the insider received 10,342 and left with 118,368 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BLUE now has a Market Capitalization of 237.07M and an Enterprise Value of 366.49M. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.91 while its Price-to-Book (P/B) ratio in mrq is 0.59. Its current Enterprise Value per Revenue stands at 16.87 whereas that against EBITDA is -2.78.
Stock Price History:
Over the past 52 weeks, BLUE has reached a high of $5.53, while it has fallen to a 52-week low of $0.88. The 50-Day Moving Average of the stock is 1.2490, while the 200-Day Moving Average is calculated to be 2.6210.
Shares Statistics:
The stock has traded on average 9.34M shares per day over the past 3-months and 6M shares per day over the last 10 days, according to various share statistics. A total of 192.74M shares are outstanding, with a floating share count of 189.83M. Insiders hold about 1.51% of the company’s shares, while institutions hold 67.31% stake in the company. Shares short for BLUE as of Mar 15, 2024 were 34.04M with a Short Ratio of 3.65, compared to 28.59M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 17.66% and a Short% of Float of 18.86%.
Earnings Estimates
Its stock is currently analyzed by 11 different market analysts. On average, analysts expect EPS of -$0.66 for the current quarter, with a high estimate of -$0.45 and a low estimate of -$0.98, while EPS last year was $0.38. The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.29 and low estimates of -$0.71.
Analysts are recommending an EPS of between -$1.27 and -$2.26 for the fiscal current year, implying an average EPS of -$1.81. EPS for the following year is -$1.66, with 13 analysts recommending between -$0.95 and -$2.86.
Revenue Estimates
11 analysts predict $10.8M in revenue for the current quarter. It ranges from a high estimate of $17.3M to a low estimate of $7.7M. As of the current estimate, Bluebird bio Inc’s year-ago sales were $62k, an estimated increase of 17,319.40% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $19.55M, an increase of 721.10% less than the figure of $17,319.40% in the same quarter last year. There is a high estimate of $30M for the next quarter, whereas the lowest estimate is $12.76M.
A total of 13 analysts have provided revenue estimates for BLUE’s current fiscal year. The highest revenue estimate was $49M, while the lowest revenue estimate was $29.5M, resulting in an average revenue estimate of $35.99M. In the same quarter a year ago, actual revenue was $3.6M, up 900.60% from the average estimate. Based on 14 analysts’ estimates, the company’s revenue will be $124.1M in the next fiscal year. The high estimate is $167.5M and the low estimate is $78M. The average revenue growth estimate for next year is up 244.80% from the average revenue estimate for this year.
